Page last updated: 2024-11-01

niclosamide and Neoplasms

niclosamide has been researched along with Neoplasms in 15 studies

Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48)
niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

ExcerptRelevanceReference
"Niclosamide is an oral antihelminthic drug used to treat parasitic infections in millions of people worldwide."4.98Niclosamide: Beyond an antihelminthic drug. ( Chen, W; Mook, RA; Premont, RT; Wang, J, 2018)
"Niclosamide is a drug used to treat parasitic infections."2.82Combination of niclosamide and current therapies to overcome resistance for cancer: New frontiers for an old drug. ( Ren, J; Wang, B; Wang, G; Wu, Q, 2022)
"Niclosamide is an FDA-approved anthelmintic drug for the treatment of parasitic infections."2.82Niclosamide as a Promising Therapeutic Player in Human Cancer and Other Diseases. ( Du, J; Liu, J; Ren, J; Wang, G; Wang, H; Wang, Z, 2022)
"The rapid development of new anticancer drugs that are safe and effective is a common goal shared by basic scientists, clinicians and patients."2.50Multi-targeted therapy of cancer by niclosamide: A new application for an old drug. ( Arend, RC; Buchsbaum, DJ; Li, PK; Li, Y; Roberts, MJ; Samant, RS, 2014)
" Overall, the HG properties, together with its natural and eco-friendly composition, create a safe and efficient platform for the local treatment of non-resectable tumors or tumors requiring pre-surgical adjuvant therapy."1.72Smart and eco-friendly N-isopropylacrylamide and cellulose hydrogels as a safe dual-drug local cancer therapy approach. ( Abasolo, I; Andrade, F; Durán-Lara, EF; Hide, D; Llaguno, M; Martell, M; Oliva, M; Rafael, D; Raurell, I; Roca-Melendres, MM; Schwartz, S; Vijayakumar, S, 2022)
"Niclosamide is an oral anthelmintic drug, approved for use against tapeworm infections."1.62Nitro-Deficient Niclosamide Confers Reduced Genotoxicity and Retains Mitochondrial Uncoupling Activity for Cancer Therapy. ( Chen, S; Cheok, CF; Elfar, GA; Ho, YS; Hor, JH; Ngai, TW; Phua, N; Yeo, P, 2021)
"Developing drugs with anticancer activity and low toxic side-effects at low costs is a challenging issue for cancer chemotherapy."1.48Pathway-Based Drug Repositioning for Cancers: Computational Prediction and Experimental Validation. ( Akiyoshi, S; Hirose, L; Iwata, M; Kohara, H; Liao, J; Sawada, R; Tani, K; Yamanishi, Y, 2018)
"), indicating its great potential as an efficacious and orally bioavailable drug candidate for human cancer therapy."1.39Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy. ( Chen, H; Chu, L; Ding, C; Liu, H; Shen, Q; Terry, K; Yang, Z; Zhang, Y; Zhou, J, 2013)

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (6.67)29.6817
2010's8 (53.33)24.3611
2020's6 (40.00)2.80

Authors

AuthorsStudies
Diamandis, P1
Wildenhain, J1
Clarke, ID1
Sacher, AG1
Graham, J1
Bellows, DS1
Ling, EK1
Ward, RJ1
Jamieson, LG1
Tyers, M1
Dirks, PB1
Chen, H1
Yang, Z1
Ding, C1
Chu, L1
Zhang, Y1
Terry, K1
Liu, H1
Shen, Q1
Zhou, J1
Lin, R1
Elf, S1
Shan, C1
Kang, HB1
Ji, Q1
Zhou, L1
Hitosugi, T1
Zhang, L1
Zhang, S1
Seo, JH1
Xie, J1
Tucker, M1
Gu, TL1
Sudderth, J1
Jiang, L1
Mitsche, M1
DeBerardinis, RJ1
Wu, S1
Li, Y3
Mao, H1
Chen, PR1
Wang, D1
Chen, GZ1
Hurwitz, SJ1
Lonial, S1
Arellano, ML1
Khoury, HJ1
Khuri, FR1
Lee, BH1
Lei, Q1
Brat, DJ1
Ye, K1
Boggon, TJ1
He, C1
Kang, S1
Fan, J1
Chen, J1
Iwata, M1
Hirose, L1
Kohara, H1
Liao, J1
Sawada, R1
Akiyoshi, S1
Tani, K1
Yamanishi, Y1
Ngai, TW1
Elfar, GA1
Yeo, P1
Phua, N1
Hor, JH1
Chen, S1
Ho, YS1
Cheok, CF1
Andrade, F1
Roca-Melendres, MM1
Llaguno, M1
Hide, D1
Raurell, I1
Martell, M1
Vijayakumar, S1
Oliva, M1
Schwartz, S1
Durán-Lara, EF1
Rafael, D1
Abasolo, I1
Ren, J2
Wang, B1
Wu, Q1
Wang, G2
Wang, Z1
Du, J1
Wang, H1
Liu, J1
Ma, R1
Ma, ZG1
Gao, JL1
Tai, Y1
Li, LJ1
Zhu, HB1
Li, L1
Dong, DL1
Sun, ZJ1
Hartleben, G1
Schorpp, K1
Kwon, Y1
Betz, B1
Tsokanos, FF1
Dantes, Z1
Schäfer, A1
Rothenaigner, I1
Monroy Kuhn, JM1
Morigny, P1
Mehr, L1
Lin, S1
Seitz, S1
Tokarz, J1
Artati, A1
Adamsky, J1
Plettenburg, O1
Lutter, D1
Irmler, M1
Beckers, J1
Reichert, M1
Hadian, K1
Zeigerer, A1
Herzig, S1
Berriel Diaz, M1
Chen, W1
Mook, RA1
Premont, RT1
Wang, J1
Barbosa, EJ1
Löbenberg, R1
de Araujo, GLB1
Bou-Chacra, NA1
Li, PK1
Roberts, MJ2
Arend, RC1
Samant, RS1
Buchsbaum, DJ1
Lu, W1
Lin, C1
Waud, WR1
Piazza, GA1
Pan, JX1
Ding, K1
Wang, CY1

Reviews

7 reviews available for niclosamide and Neoplasms

ArticleYear
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
    Nature cell biology, 2015, Volume: 17, Issue:11

    Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms;

2015
Combination of niclosamide and current therapies to overcome resistance for cancer: New frontiers for an old drug.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 155

    Topics: Antineoplastic Agents; Drug Delivery Systems; Humans; Neoplasms; Niclosamide; Water

2022
Niclosamide as a Promising Therapeutic Player in Human Cancer and Other Diseases.
    International journal of molecular sciences, 2022, Dec-17, Volume: 23, Issue:24

    Topics: Anthelmintics; Humans; Neoplasms; Niclosamide; Signal Transduction; Vascular Diseases

2022
Niclosamide: Beyond an antihelminthic drug.
    Cellular signalling, 2018, Volume: 41

    Topics: Animals; Anthelmintics; Arthritis, Rheumatoid; Diabetes Mellitus, Type 2; Disease Models, Animal; En

2018
Niclosamide repositioning for treating cancer: Challenges and nano-based drug delivery opportunities.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2019, Volume: 141

    Topics: Animals; Antineoplastic Agents; Drug Compounding; Drug Delivery Systems; Drug Repositioning; Humans;

2019
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.
    Cancer letters, 2014, Jul-10, Volume: 349, Issue:1

    Topics: Animals; Antineoplastic Agents; Humans; Molecular Targeted Therapy; Neoplasms; Neoplastic Stem Cells

2014
Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells.
    Chinese journal of cancer, 2012, Volume: 31, Issue:4

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; Mechani

2012

Other Studies

8 other studies available for niclosamide and Neoplasms

ArticleYear
Chemical genetics reveals a complex functional ground state of neural stem cells.
    Nature chemical biology, 2007, Volume: 3, Issue:5

    Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic

2007
Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy.
    European journal of medicinal chemistry, 2013, Volume: 62

    Topics: Animals; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; D

2013
Pathway-Based Drug Repositioning for Cancers: Computational Prediction and Experimental Validation.
    Journal of medicinal chemistry, 2018, 11-08, Volume: 61, Issue:21

    Topics: Antineoplastic Agents; Computational Biology; Drug Repositioning; Neoplasms

2018
Nitro-Deficient Niclosamide Confers Reduced Genotoxicity and Retains Mitochondrial Uncoupling Activity for Cancer Therapy.
    International journal of molecular sciences, 2021, Sep-27, Volume: 22, Issue:19

    Topics: DNA Damage; HCT116 Cells; Humans; Mitochondria; Neoplasms; Niclosamide

2021
Smart and eco-friendly N-isopropylacrylamide and cellulose hydrogels as a safe dual-drug local cancer therapy approach.
    Carbohydrate polymers, 2022, Nov-01, Volume: 295

    Topics: Acrylamides; Cellulose; Doxorubicin; Humans; Hydrogels; Neoplasms; Niclosamide; Temperature

2022
Injectable pegylated niclosamide (polyethylene glycol-modified niclosamide) for cancer therapy.
    Journal of biomedical materials research. Part A, 2020, Volume: 108, Issue:1

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Liberation; Humans; Injections

2020
Combination therapies induce cancer cell death through the integrated stress response and disturbed pyrimidine metabolism.
    EMBO molecular medicine, 2021, 04-09, Volume: 13, Issue:4

    Topics: Antineoplastic Agents; Cell Death; Humans; Neoplasms; Niclosamide; Pyrimidines

2021
Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway.
    PloS one, 2011, Volume: 6, Issue:12

    Topics: Adaptor Proteins, Signal Transducing; Apoptosis; beta Catenin; Breast Neoplasms; Cell Line, Tumor; C

2011